Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.56 |
|---|---|
| High | 2.60 |
| Low | 2.31 |
| Bid | 2.51 |
| Offer | 2.53 |
| Previous close | 2.55 |
| Average volume | 1.31m |
|---|---|
| Shares outstanding | 54.22m |
| Free float | 39.76m |
| P/E (TTM) | -- |
| Market cap | 138.26m USD |
| EPS (TTM) | -2.01 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 19:45 GMT.
More ▼
Announcements
- ALX Oncology Announces Pricing of Underwritten Offering
- New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
- ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
- ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
- ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
- ALX Oncology to Present at Upcoming Investor Conferences
- ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
- ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
- ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
More ▼
